Skip to main content
Journal cover image

Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial

Publication ,  Conference
Green, MMB; Horwitz, ME; Kang, Y; Chao, NJ; Long, GD; Rizzieri, D; Gasparetto, C; Sung, AD; Sarantopoulos, S; Li, Z; Corbet, K; Sullivan, K ...
Published in: Biology of Blood and Marrow Transplantation
February 2015

Duke Scholars

Published In

Biology of Blood and Marrow Transplantation

DOI

ISSN

1083-8791

Publication Date

February 2015

Volume

21

Issue

2

Start / End Page

S31 / S32

Publisher

Elsevier BV

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Green, M. M. B., Horwitz, M. E., Kang, Y., Chao, N. J., Long, G. D., Rizzieri, D., … Stuart, R. (2015). Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial. In Biology of Blood and Marrow Transplantation (Vol. 21, pp. S31–S32). Elsevier BV. https://doi.org/10.1016/j.bbmt.2014.11.024
Green, Michael M. B., Mitchell E. Horwitz, Yubin Kang, Nelson J. Chao, Gwynn D. Long, David Rizzieri, Cristina Gasparetto, et al. “Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial.” In Biology of Blood and Marrow Transplantation, 21:S31–32. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.024.
Green MMB, Horwitz ME, Kang Y, Chao NJ, Long GD, Rizzieri D, et al. Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial. In: Biology of Blood and Marrow Transplantation. Elsevier BV; 2015. p. S31–2.
Green, Michael M. B., et al. “Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial.” Biology of Blood and Marrow Transplantation, vol. 21, no. 2, Elsevier BV, 2015, pp. S31–32. Crossref, doi:10.1016/j.bbmt.2014.11.024.
Green MMB, Horwitz ME, Kang Y, Chao NJ, Long GD, Rizzieri D, Gasparetto C, Sung AD, Sarantopoulos S, Li Z, Corbet K, Riggan-Stuelke E, Sullivan K, Wilson B, Chhabra S, Costa LV, Mims A, Stuart R. Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial. Biology of Blood and Marrow Transplantation. Elsevier BV; 2015. p. S31–S32.
Journal cover image

Published In

Biology of Blood and Marrow Transplantation

DOI

ISSN

1083-8791

Publication Date

February 2015

Volume

21

Issue

2

Start / End Page

S31 / S32

Publisher

Elsevier BV

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences